candesartan cilexetil has been researched along with Cardiac Hypertrophy in 18 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim was to investigate changes in cardiac transforming growth factor beta 1 (TGF-beta 1), fibronectin, and collagen types I and III mRNA levels in isoprenaline induced cardiac hypertrophy, and the effects of delapril, an angiotensin converting enzyme inhibitor, and TCV-116, an angiotensin II type 1 receptor antagonist, on this hypertrophy." | 7.69 | Transforming growth factor beta 1 and extracellular matrix gene expression in isoprenaline induced cardiac hypertrophy: effects of inhibition of the renin-angiotensin system. ( Iwao, H; Kim, S; Omura, T; Takeda, T; Takeuchi, K, 1994) |
| "To determine whether angiotensin II participates in the pathogenesis of cardiac hypertrophy and impairs coronary circulation in DOCA/salt hypertension, DOCA hypertensive rats were treated with candesartan cilexetil for 8 wk." | 7.69 | Chronic angiotensin blockade with candesartan cilexetil in DOCA/salt hypertensive rats reduces cardiac hypertrophy and coronary resistance without affecting blood pressure. ( Fujita, H; Itoh, H; Kawa, T; Miki, S; Morimoto, S; Nakagawa, M; Nakata, T; Sasaki, S; Takeda, K; Uchida, A, 1997) |
| "These results suggest that ISO-induced cardiac hypertrophy is mediated, at least in part, by IGF-I, the expression of which is upregulated through the activation of AT1 receptor." | 5.30 | Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy. ( Ikeda, J; Miura, S; Nawata, J; Ohno, I; Shirato, K; Suzuki, J, 1999) |
| "We investigated the effects of an angiotensin II type 1 (AT1)-receptor antagonist on experimental cardiac hypertrophy, vascular thickening and nephrosclerosis, in order to determine the involvement of this receptor in the development of cardiovascular and renal damage." | 4.79 | Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and the cellular phenotype. ( Iwao, H; Kim, S, 1997) |
| " Stroke-prone spontaneously hypertensive Izumo strain rats were divided into four groups, treated with vehicle, the angiotensin-converting enzyme inhibitor (ACEI) delapril (40 mg/kg per d), the angiotensin receptor antagonist (AT1R-Ant) candesartan cilexetil (1 mg/kg per d), or the vasodilator hydralazine (25 mg/kg per d) from weaning to puberty (3 to 10 wk of age), and then monitored without treatment for 6 mo." | 3.71 | Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. ( Hayashi, M; Nakaya, H; Saruta, T; Sasamura, H, 2001) |
| "The aim was to investigate changes in cardiac transforming growth factor beta 1 (TGF-beta 1), fibronectin, and collagen types I and III mRNA levels in isoprenaline induced cardiac hypertrophy, and the effects of delapril, an angiotensin converting enzyme inhibitor, and TCV-116, an angiotensin II type 1 receptor antagonist, on this hypertrophy." | 3.69 | Transforming growth factor beta 1 and extracellular matrix gene expression in isoprenaline induced cardiac hypertrophy: effects of inhibition of the renin-angiotensin system. ( Iwao, H; Kim, S; Omura, T; Takeda, T; Takeuchi, K, 1994) |
| "Recently, it has been suggested that angiotensin II (AII) might be associated with cardiac hypertrophy and fibrosis." | 3.69 | Angiotensin II receptor antagonist, TCV-116, prevents myocardial hypertrophy in spontaneously hypertensive rats. ( Dohi, K; Iwano, M; Kagoshima, T; Konishi, N; Masuda, J; Nakamura, Y; Sakaguchi, Y; Sutani, T; Tsuchihashi, M; Tsuruta, S, 1994) |
| "To determine whether angiotensin II participates in the pathogenesis of cardiac hypertrophy and impairs coronary circulation in DOCA/salt hypertension, DOCA hypertensive rats were treated with candesartan cilexetil for 8 wk." | 3.69 | Chronic angiotensin blockade with candesartan cilexetil in DOCA/salt hypertensive rats reduces cardiac hypertrophy and coronary resistance without affecting blood pressure. ( Fujita, H; Itoh, H; Kawa, T; Miki, S; Morimoto, S; Nakagawa, M; Nakata, T; Sasaki, S; Takeda, K; Uchida, A, 1997) |
| "Therefore, for the treatment of hypertension it is important to understand the mechanism of cardiac hypertrophy and to establish effective pharmaceutical interventions." | 2.40 | Role of the renin-angiotensin system in cardiac hypertrophy. ( Komuro, I; Yamazaki, T; Yazaki, Y, 1999) |
| "Treatment with imidapril significantly prevented the L-NAME-induced increase in the gene expression and immunoreactivity of PAI-1, but candesartan cilexetil showed no such effect." | 1.31 | Differential effects of imidapril and candesartan cilexetil on plasminogen activator inhibitor-1 expression induced by prolonged inhibition of nitric oxide synthesis in rat hearts. ( Egashira, K; Katoh, M; Mitsui, T; Narita, H; Takeshita, A, 2000) |
| "Cardiac hypertrophy was reduced by all three treatments, but to a lesser extent by hydralazine (treatment study), and this regression of cardiac hypertrophy persisted only with both types of RAS inhibition (withdrawal study)." | 1.31 | Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats. ( Paull, JR; Widdop, RE, 2001) |
| "Cardiac hypertrophy was induced by constricting the abdominal aorta above the renal arteries." | 1.30 | Pressure overload per se rather than cardiac angiotensin converting enzyme activity may be important in the development of rat cardiac hypertrophy. ( Hayakawa, T; Ito, T; Matsui, H; Morishima, I; Mukawa, H; Okumura, K; Shimauchi, A; Toki, Y, 1997) |
| "These results suggest that ISO-induced cardiac hypertrophy is mediated, at least in part, by IGF-I, the expression of which is upregulated through the activation of AT1 receptor." | 1.30 | Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy. ( Ikeda, J; Miura, S; Nawata, J; Ohno, I; Shirato, K; Suzuki, J, 1999) |
| "Furthermore, TCV-116 regressed cardiac hypertrophy and lessened the medial hypertrophy of the aorta in SHRSP." | 1.29 | Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. ( Chatani, F; Hamaguchi, A; Inada, Y; Ishimura, Y; Iwao, H; Kim, S; Miura, K; Ohta, K; Omura, T; Yukimura, T, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (72.22) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawamura, M | 1 |
| Itoh, H | 3 |
| Yura, S | 1 |
| Mogami, H | 1 |
| Fujii, T | 1 |
| Kanayama, N | 1 |
| Konishi, I | 1 |
| Jones, ES | 1 |
| Black, MJ | 1 |
| Widdop, RE | 2 |
| Mori, T | 1 |
| Nishimura, H | 1 |
| Ueyama, M | 1 |
| Kubota, J | 1 |
| Kawamura, K | 1 |
| Kim, S | 3 |
| Ohta, K | 1 |
| Hamaguchi, A | 1 |
| Omura, T | 2 |
| Yukimura, T | 1 |
| Miura, K | 1 |
| Inada, Y | 3 |
| Ishimura, Y | 2 |
| Chatani, F | 1 |
| Iwao, H | 3 |
| Takeuchi, K | 1 |
| Takeda, T | 1 |
| Kagoshima, T | 1 |
| Masuda, J | 1 |
| Sutani, T | 1 |
| Sakaguchi, Y | 1 |
| Tsuchihashi, M | 1 |
| Tsuruta, S | 1 |
| Iwano, M | 1 |
| Dohi, K | 1 |
| Nakamura, Y | 1 |
| Konishi, N | 1 |
| Takeda, K | 2 |
| Fujita, H | 2 |
| Nakamura, K | 1 |
| Uchida, A | 2 |
| Tanaka, M | 1 |
| Nakata, T | 2 |
| Sasaki, S | 2 |
| Nakagawa, M | 2 |
| Wada, T | 1 |
| Ojima, M | 1 |
| Sanada, T | 1 |
| Shibouta, Y | 1 |
| Kanagawa, R | 1 |
| Fujisawa, Y | 1 |
| Nishikawa, K | 1 |
| Mukawa, H | 1 |
| Toki, Y | 1 |
| Shimauchi, A | 1 |
| Matsui, H | 1 |
| Morishima, I | 1 |
| Okumura, K | 1 |
| Ito, T | 1 |
| Hayakawa, T | 1 |
| Obayashi, M | 1 |
| Yano, M | 1 |
| Kohno, M | 1 |
| Kobayashi, S | 1 |
| Tanigawa, T | 1 |
| Hironaka, K | 1 |
| Ryouke, T | 1 |
| Matsuzaki, M | 1 |
| Murakami, M | 1 |
| Tazawa, S | 1 |
| Nakao, K | 1 |
| Komatsu, H | 1 |
| Miki, S | 1 |
| Morimoto, S | 1 |
| Kawa, T | 1 |
| Suzuki, J | 1 |
| Ohno, I | 1 |
| Nawata, J | 1 |
| Miura, S | 1 |
| Ikeda, J | 1 |
| Shirato, K | 1 |
| Yamazaki, T | 1 |
| Komuro, I | 1 |
| Yazaki, Y | 1 |
| Katoh, M | 1 |
| Egashira, K | 1 |
| Mitsui, T | 1 |
| Takeshita, A | 1 |
| Narita, H | 1 |
| Nakaya, H | 1 |
| Sasamura, H | 1 |
| Hayashi, M | 1 |
| Saruta, T | 1 |
| Paull, JR | 1 |
2 reviews available for candesartan cilexetil and Cardiac Hypertrophy
| Article | Year |
|---|---|
Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and the cellular phenotype.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 1997 |
Role of the renin-angiotensin system in cardiac hypertrophy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 1999 |
16 other studies available for candesartan cilexetil and Cardiac Hypertrophy
| Article | Year |
|---|---|
Angiotensin II receptor blocker candesartan cilexetil, but not hydralazine hydrochloride, protects against mouse cardiac enlargement resulting from undernutrition in utero.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Caloric Restriction; Cardiomegaly; Disease Models, Anim | 2009 |
Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Block | 2004 |
Comparable effects of angiotensin II and converting enzyme blockade on hemodynamics and cardiac hypertrophy in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1995 |
Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Benzimidazoles; Biphenyl Compounds | 1995 |
Transforming growth factor beta 1 and extracellular matrix gene expression in isoprenaline induced cardiac hypertrophy: effects of inhibition of the renin-angiotensin system.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blotting, Nor | 1994 |
Angiotensin II receptor antagonist, TCV-116, prevents myocardial hypertrophy in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 1994 |
Effect of an angiotensin II receptor antagonist, TCV-116, on cardiac hypertrophy and coronary circulation in spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arginine; Benzimidazoles; Biphen | 1994 |
Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Angiote | 1997 |
Pressure overload per se rather than cardiac angiotensin converting enzyme activity may be important in the development of rat cardiac hypertrophy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1997 |
Dose-dependent effect of ANG II-receptor antagonist on myocyte remodeling in rat cardiac hypertrophy.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood | 1997 |
Effects of the new angiotensin receptor antagonist dipotassium (Z)-2-[[5-ethyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl-1,3,4-thiadiazoline-2-ylidene]aminocarbonyl]-1-cy clopentencarbox ylate on experimental cardiac hypertrophy and acute left ventric
Topics: Acute Disease; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Cardio | 1997 |
Chronic angiotensin blockade with candesartan cilexetil in DOCA/salt hypertensive rats reduces cardiac hypertrophy and coronary resistance without affecting blood pressure.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body | 1997 |
Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy.
Topics: Adrenergic beta-Agonists; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzim | 1999 |
Differential effects of imidapril and candesartan cilexetil on plasminogen activator inhibitor-1 expression induced by prolonged inhibition of nitric oxide synthesis in rat hearts.
Topics: Actins; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihyp | 2000 |
Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angioten | 2001 |
Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 2001 |